Poly(D,L-lactic acid) (PLA) and poly(D,L-lactic-co-glycolic acid) (PLGA) can optimize the release kinetics of final drug products, reducing side effects while improving patient comfort and compliance. Our wide portfolio of top-quality biodegradable polymers has an excellent track record of customer and FDA audits and is manufactured in Europe to robust QC specifications developed with the end dosage form in mind. You also have the option of using our customization capabilities to manufacture a polymer with the characteristics you need.
Benefits of our PLA and PLGA polymer portfolio include:
Flyer: PLA and PLGA Polymer Portfolio for Peptide and Small Molecule Formulation
Tool: Formulation Product Finder
Webinar: Critical Quality Factors of Biodegradable Polymers for Injectable Sustained-release Formulations
Webinar: Polymer Based Drug Delivery Systems for Parenteral Controlled Release: From Small Molecules to Biologics